Skip to content

Liraglutide Stacking Guide: Best Combinations & Protocols (2026)

From Peptidepedia, the trusted peptide wiki.

Stacking

Liraglutide is sometimes used alongside other medications, though combinations should be approached with caution and medical supervision.

With metformin: This is the most well-established combination, commonly used in type 2 diabetes management. Metformin and liraglutide have complementary mechanisms, and their combined use is supported by extensive clinical data. Additive weight loss benefits have been observed.

With insulin: Victoza is approved for use alongside basal insulin in patients with type 2 diabetes. The SCALE Insulin trial demonstrated that adding liraglutide to basal insulin improved both weight and glycemic control. Hypoglycemia risk increases when liraglutide is combined with insulin, and insulin dose reduction may be necessary.

With other GLP-1 agonists: Simultaneous use of liraglutide with semaglutide, tirzepatide, or other GLP-1 agonists is not recommended. The mechanisms overlap completely, and combining them would dramatically increase gastrointestinal side effects without meaningful additional benefit.

With growth hormone peptides: Some users in the bodybuilding and fitness community combine liraglutide with growth hormone secretagogues such as ipamorelin or sermorelin for body recomposition. This combination is experimental and off-label. Caution is warranted as both compound classes affect glucose metabolism.

Frequently Asked Questions

Both contain liraglutide but are approved for different indications and at different doses. Victoza is dosed at 1.2 to 1.8 mg daily for type 2 diabetes, while Saxenda is dosed at 3.0 mg daily for chronic weight management. They should not be used together, and Saxenda should not be used as a diabetes treatment.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015;373(1):11-22.
  2. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
  3. Davies MJ, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes (SCALE Diabetes). JAMA. 2015;314(7):687-699.
  4. Wadden TA, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy for Obesity in Primary Care (SCALE IBT). Obesity. 2020;28(3):529-536.
  5. Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128.
  6. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155.
  7. Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022;327(2):138-150.
  8. Wadden TA, et al. Weight Maintenance and Additional Weight Loss With Liraglutide After Low-Calorie-Diet-Induced Weight Loss (SCALE Maintenance). Int J Obes. 2013;37(11):1443-1451.
  9. FDA Approval of Saxenda for Weight Management in Patients Aged 12 and Older (2020).
  10. Saxenda (liraglutide) Prescribing Information. Novo Nordisk. 2023.
  11. Victoza (liraglutide) Prescribing Information. Novo Nordisk. 2023.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”